The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration

Bosscha, Machteld I.; Dissel, Jaap T. van; Kuijper, Ed J.; Swart, W.A.J.M.; Jager, M. J.

doi:10.1136/bjo.88.1.25

Cited by 23 publications

(12 citation statements)

References 17 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[36], and to the limited ocular penetration of antifungals [37]. Notably, PMB can be formulated for ophthalmic use [16], which is described as a highly effective drug on bacterial corneal ulcerations [38]. Moreover, the use of such antimicrobial agent constitutes a potential alternative treatment that may improve the outcome in some critical infections caused by MDR fungi, such as the recent MDR Fusarium keratitis-case report in a 46-year-old man who was still declining even the maximal therapeutic support and therapeutic keratoplasty [36].…”

Section: Discussionmentioning

confidence: 99%

In vitro polymyxin activity against clinical multidrug-resistant fungi

Yousfi

Ranque

Rolain

et al. 2019

Antimicrob Resist Infect Control

View full text Add to dashboard Cite

Background Although antifungals are available and usually used against fungal infections, multidrug-resistant (MDR) fungal pathogens are a growing problem for public health. Moreover, fungal infections have become more prevalent nowadays due to the increasing number of people living with immunodeficiency. Thus, previously rarely-isolated and/or unidentified fungal species including MDR yeast and moulds have emerged around the world. Recent works indicate that polymyxin antibiotics (polymyxin B and colistin) have potential antifungal proprieties. Therefore, investigating the in vitro activity of these molecules against clinical multidrug-resistant yeast and moulds could be very useful. Methods In this study, a total of 11 MDR yeast and filamentous fungal strains commonly reported in clinical settings were tested against polymyxin antibiotics. These include strains belonging to the Candida , Cryptococcus and Rhodotorula yeast genera, along with others belonging to the Aspergillus , Fusarium , Scedosporium , Lichtheimia and Rhizopus mould genera. The fungicidal or fungistatic action of colistin against clinical yeast strains was determined by the time-kill study. Further, a checkerboard assay for its combination with antifungal agents, usually used in clinical practices (amphotericin B, itraconazole, voriconazole), was carried out against multi-drug resistant fungal strains. Results Polymyxin B and colistin exhibited an antifungal activity against all MDR fungal strains tested with MICs ranging from 16 to 128 μg/ml, except for the Aspergillus species. In addition, colistin has a fungicidal action against yeast species, with minimum fungicidal concentrations ranging from 2 to 4 times MICs. It induces damage to the MDR Candida albicans membrane. A synergistic activity of colistin-amphotericin B and colistin-itraconazole associations against Candida albicans and Lichtheimia corymbifera strains, respectively, and colistin-fluconazole association against Rhodotorula mucilaginosa, was demonstrated using a checkerboard microdilution assay. Conclusion colistin could be proposed, in clinical practice, in association with other antifungals, to treat life-threatening fungal infections caused by MDR yeasts or moulds.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro polymyxin activity against clinical multidrug-resistant fungi

Yousfi

Ranque

Rolain

et al. 2019

Antimicrob Resist Infect Control

View full text Add to dashboard Cite

show abstract

“…No serious adverse events were reported, although 8% of patients reported toxic punctate epitheliopathy or allergic reactions. 30 Similarly, combination trimethoprim and polymyxin B was well tolerated in a bacterial conjunctivitis study, with a 7% rate of adverse effects noted. 31…”

Section: Polymyxin B-based Formulationsmentioning

confidence: 94%

Limitations of Current Antibiotics for the Treatment of Bacterial Conjunctivitis

Karpecki

Paterno

Comstock

2010

Optometry and Vision Science

View full text Add to dashboard Cite

Bacterial conjunctivitis is a common ocular infection that is generally treated empirically with a broad-spectrum antibiotic. The more common pathogens causing bacterial conjunctivitis include Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus epidermidis, and Moraxella species. Several antibiotics traditionally used to treat bacterial conjunctivitis are no longer widely prescribed because of increased bacterial resistance and/or safety concerns. The introduction of the fluoroquinolone class of anti-infectives offered effective and better tolerated treatment options. Nonetheless, successful therapy for bacterial conjunctivitis continues to be limited by several factors. A primary concern is the development of bacterial resistance that may be impacted not only by widespread antibiotic use but also by antibacterial pharmacokinetics, such as maintenance of insufficient bactericidal concentrations at the site of infection. In addition, poor adherence to prescribed regimens that require frequent administration, along with undesirable adverse events, affects the development of bacterial resistance and the success of treatment regimens. This article reviews current antibacterial agents used to treat bacterial conjunctivitis, factors that limit their successful use in treatment, and options for future development of more effective topical ophthalmic anti-infective agents.

show abstract

“…Bacitracin is probably most effective against gram-positive organisms, neomycin is effective against most gram-positive and gram-negative bacteria (with the exception of Pseudomonas), and polymyxin B is effective against gram-negative bacteria including Pseudomonas. 3,29…”

Section: Discussionmentioning

confidence: 99%

Bandages, dressings, and cranial neurosurgery

Winston¹,

McBride²,

Dudekula³

2007

Journal of Neurosurgery: Pediatrics

View full text Add to dashboard Cite

A total of 702 operations were performed in 577 patients; only five patients received any type of surgical bandaging. There were four SSIs (0.57%; 95% confidence interval [CI] 0.16-1.45). The postoperative infection rate in the 626 clean cases was 0.48% (95% CI 0.10-1.39) and was 2.63% (95% CI 0.07-13.81) in the 38 clean-contaminated cases. The data obtained in this investigation is consistent with the position that bandaging incisional scalp wounds after cranial surgery adds little if any benefit beyond the easier, simpler, and cheaper practice of using antibiotic ointment as a dressing without bandaging.

show abstract

The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration

Cited by 23 publications

References 17 publications

In vitro polymyxin activity against clinical multidrug-resistant fungi

In vitro polymyxin activity against clinical multidrug-resistant fungi

Limitations of Current Antibiotics for the Treatment of Bacterial Conjunctivitis

Bandages, dressings, and cranial neurosurgery

Contact Info

Product

Resources

About